Abstract
Cloned in 1992, Jak2 tyrosine kinase has emerged as a critical molecule in mammalian development, physiology, and disease. Here, we will review the early history of Jak2 as it pertains to its role in classical cellular signaling. We also review how specific structural determinants within Jak2 dictate its overall function. Finally, we will review relatively recent literature as it pertains to the role of Jak2 in neoplastic growth as well as the identification of novel Jak2 inhibitors. It is our hope that by reviewing these specific areas, we will have a better understanding of the role of Jak2 in cancer, and in turn, we may have a better idea as to how to block aberrant Jak2 function.
Keywords: Jak2, tyrosine kinase, cancer, signal transduction, gene transcription
Anti-Cancer Agents in Medicinal Chemistry
Title: Jak2 Tyrosine Kinase and Cancer: How Good Cells Get HiJAKed
Volume: 7 Issue: 6
Author(s): Michael D. Godeny and Peter P. Sayeski
Affiliation:
Keywords: Jak2, tyrosine kinase, cancer, signal transduction, gene transcription
Abstract: Cloned in 1992, Jak2 tyrosine kinase has emerged as a critical molecule in mammalian development, physiology, and disease. Here, we will review the early history of Jak2 as it pertains to its role in classical cellular signaling. We also review how specific structural determinants within Jak2 dictate its overall function. Finally, we will review relatively recent literature as it pertains to the role of Jak2 in neoplastic growth as well as the identification of novel Jak2 inhibitors. It is our hope that by reviewing these specific areas, we will have a better understanding of the role of Jak2 in cancer, and in turn, we may have a better idea as to how to block aberrant Jak2 function.
Export Options
About this article
Cite this article as:
Godeny D. Michael and Sayeski P. Peter, Jak2 Tyrosine Kinase and Cancer: How Good Cells Get HiJAKed, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/187152007782330105
DOI https://dx.doi.org/10.2174/187152007782330105 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ANN and Bayesian Classification Models for Virtual Screening of Endocrine-Disrupting Chemicals
Combinatorial Chemistry & High Throughput Screening The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Synthesis and Antitumor/Antiviral Evaluation of 6–Thienyl–5–cyano-2–thiouracil Derivatives and Their Thiogalactosides Analogs
Current Organic Synthesis Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update
Reviews on Recent Clinical Trials Free Fatty Acids-Sensing G Protein-Coupled Receptors in Drug Targeting and Therapeutics
Current Medicinal Chemistry Administration of Human Umbilical Cord Blood Cells Produces Interleukin-10 (IL-10) in IL-10 Deficient Mice Without Immunosuppression
Current Stem Cell Research & Therapy Near-Infrared Quantum Dots as Optical Probes for Tumor Imaging
Current Topics in Medicinal Chemistry Current Progresses and Trends in the Development of Progesterone Receptor Modulators
Current Medicinal Chemistry Effects of Natural Compounds on Xenopus Embryogenesis: A Potential Read Out for Functional Drug Discovery Targeting Wnt/β-catenin Signaling
Current Topics in Medicinal Chemistry Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics
Current Drug Targets DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Regulation of MMPs During Melanoma Progression: From Genetic to Epigenetic
Anti-Cancer Agents in Medicinal Chemistry In-silico ADME Studies for New Drug Discovery: From Chemical Compounds to Chinese Herbal Medicines
Current Drug Metabolism Development of Radicicol Analogues
Current Cancer Drug Targets Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer
Current Pharmaceutical Design Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Patent Selections
Recent Patents on Drug Delivery & Formulation